牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-081919 Act: 34 Size: 21 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-081399 Act: 34 Size: 24 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-081373 Act: 34 Size: 23 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-081288 Act: 34 Size: 20 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-079717 Act: 34 Size: 24 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002642 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002602 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-074563 Act: 34 Size: 5 MB 网页链接
$灿菲特生物制药(CANF)$ F-3 Registration statement by foreign private issuers Accession Number: 0001213900-23-073236 Act: 33 Size: 619 KB 网页链接
$灿菲特生物制药(CANF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001213900-23-073240 Act: 33 Size: 549 KB 网页链接